On top of $800m initially, Medtronic will pay performance fees to acquire portfolio company Ardian.

Medtronic, a New York-listed medical device maker, has agreed to acquire one of its corporate venturing unit’s portfolio companies, Ardian, for at least $800m.

On top of the $800m, the acquirer said it would pay performance fees equal to the annual revenue growth through the end of Medtronic’s fiscal year 2015.

Medtronic owned 11% of US-based Ardian, which makes the Symplicity Catheter System to treat hypertension and related blood conditions.

Medtronic led Ardian’s $47m series C round in March…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?